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Abstract 
Background: Plasmodium circumsporozoite protein (CSP) is a major surface antigen present in the sporozoite (Spz) 
stage of a malaria parasite. RTS, S vaccine, the most clinically advanced malaria vaccine, consists of a large portion 
of Plasmodium falciparum CSP (PfCSP). A highly infectious, recombinant rodent malaria, Plasmodium yoelii parasite 
bearing a full-length PfCSP, PfCSP/Py Spz, was needed as a tool to evaluate the role of PfCSP in mediating, protective, 
anti-malaria immunity in a mouse model.
Methods: A transgenic parasite, PfCSP/Py Spz, was generated by inserting a construct expressing the PfCSP at the 
locus of the P. yoelii CSP gene by double cross-over homologous recombination. Then the biological and protective 
properties of PfCSP/Py Spz were determined.
Results: This PfCSP/Py parasite produced up to 30,000 Spz in mosquito salivary glands, which is equal or even higher 
than the number of Spz produced by wild-type P. yoelii parasites. Five bites of PfCSP/Py-infected mosquitoes could 
induce blood infection in BALB/c mice.
Conclusions: The current study has demonstrated a successful establishment of a transgenic P. yoelii parasite clone 
that is able to express a full-length PfCSP, PfCSP/Py parasite. Importantly, this PfCSP/Py parasite can be as infectious as 
the wild-type P. yoelii parasite both in mosquito vector and in mouse, a mammalian host. A new transgenic parasite 
that expresses a full-length PfCSP may become a useful tool for researchers to investigate immunity against PfCSP in a 
mouse model.
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Background
There were 198 million cases of malaria (with an uncer-
tainty range of 124–283 million) in 2013, which led to 
584,000 fatalities (uncertainty range of 367,000–755,000) 
[1]. Malaria is transmitted among humans by female 
mosquitoes of the genus Anopheles. Sporozoites (Spz) 
are the infectious forms of malaria parasites residing in 
mosquito salivary glands [2, 3]. Radiation or genetically 
attenuated whole Spz vaccine candidates target the pre-
erythrocytic stages in the life cycle of the parasite [4–6] 
and are shown to be highly protective, but they are chal-
lenging to mass manufacture and administer [2, 7, 8]. The 
circumsporozoite protein (CSP) is an immunodominant 
protective antigen present in malaria Spz [9, 10]. CSP is 
also a major component of the most advanced malaria 
vaccine candidate, RTS,S/AS01, also called Mosquirix®, 
which has been licensed for use in endemic countries by 
the European Medicines Agency [2]. A clinical phase III 
trial evaluated the vaccine efficacy against all episodes 
of severe malaria be approximately 50  % in young chil-
dren in Africa [11, 12]. There was a correlation between 
Open Access
Malaria Journal
*Correspondence:  iwanaga@doc.medic.mie-u.ac.jp;  
m-yuda@doc.medic.mie-u.ac.jp; mtsuji@adarc.org 
1 HIV and Malaria Vaccine Program, Aaron Diamond AIDS Research Center, 
Affiliate of The Rockefeller University, New York, NY, USA
3 Department of Medical Zoology, Mie University Graduate School 
of Medicine, Tsu, Mie, Japan
Full list of author information is available at the end of the article
Page 2 of 8Zhang et al. Malar J  (2016) 15:201 
antibody titres against Plasmodium falciparum CSP 
(PfCSP) and the degree of protection in both the RTS,S/
AS01 vaccine and whole Spz vaccine, but the role of cell-
mediated immunity in protection induced by the vac-
cines was not clear [13].
A recombinant rodent parasite, PfPb parasite, Plasmo-
dium berghei bearing only the central repeat region of 
PfCSP, which is from the human parasite P. falciparum, 
was generated to study protective humoral immunity 
induced by the PfCSP central repeat [8, 14–16]. PfPb 
parasites were also used to investigate the in vivo protec-
tion induced by the anti-PfCSP monoclonal antibodies 
(mAbs) delivered by adeno-associated, virus-based gene 
transfer [17]. The lack of both N-terminal and C-termi-
nal in the PfPb parasite is a drawback for its use in the 
analysis of protective immunity mediated by T-cells as 
the non-repeat regions contain the majority of the CD4+ 
and CD8+ T cell epitopes of PfCSP [18–20]. Recently, a 
recombinant P. berghei parasite expressing a full-length 
PfCSP was generated, but the parasite’s infectivity was 
very low in the mosquito salivary gland [21, 22].
Here, the current study describes the generation of a 
highly infectious, recombinant rodent malaria parasite, 
PfCSP/Py, a Plasmodium yoelii parasite expressing a 
full-length PfCSP, instead of P. yoelii CSP (PyCSP). This 
hybrid parasites’ level of infection in mosquito salivary 
gland is around 20,000–30,000/mosquito, and in  vivo 
infectivity is equal to or higher than that of wild-type P. 
yoelii. This PfCSP/Py parasite provides malaria research-
ers with an effective tool to study the T-cell and antibody-
mediated immune responses induced by a full-length 
PfCSP, as well as the protective efficacy of a full-length 
PfCSP-based vaccine in mice.
Methods
Mice
Six-week old female BALB/c mice were purchased from 
the Jackson Laboratory (Bar Harbor, ME, USA) and were 
maintained under standard conditions in the Labora-
tory Animal Research Center of The Rockefeller Uni-
versity. All animal experiments were carried out in strict 
accordance with the Policy on Humane Care and Use of 
Laboratory Animals of the US Public Health Service. The 
protocol was approved by the Institutional Animal Care 
and Use Committee (IACUC) at The Rockefeller Univer-
sity (Assurance # A3081-01).
Construction of transgenic parasites
Transgenic parasites were generated by inserting the 
PfCSP expression construct at the locus of the P. yoelii 
CSP gene by double cross-over homologous recombina-
tion (Fig. 1). The targeting plasmid for generating PfCSP/
Py parasites was generated in a pBluescript plasmid that 
contains the PyCSP promoter, PfCSP coding sequence, 
3′UTR of HSP70, human DHFR expression cassette, and 
3′UTR of PyCSP. The plasmid was linearized by diges-
tion with restriction enzymes KpnI and NotI. Transfec-
tion of P. yoelii 17XNL strain [23] was performed by the 
same procedures as described previously [24] except that 
a discontinuous gradient of Percoll/sorbitol (60/40  %) 
was used for purification of mature schizonts instead of 
Nycodentz. After transfection, parasites were selected 
by pyrimethamine in drinking water. Then, the resist-
ant populations were single cloned by limiting dilution 
in mice. Correct targeting was checked by gDNA PCR. 
Primers used in these experiments were listed in Table 1.
Measurement of the number of Spz in the mid‑gut 
and salivary glands of mosquitoes
Approximately 300 female Anopheles stephensi mos-
quitoes were allowed to feed on a group of five Swiss-
Webster mice infected with 0.1  % gametocyte of either 
wild-type P. yoelii 17XNL parasites or PfCSP/Py para-
sites, as previously described [25, 26]. Then, the midguts 
and salivary glands were dissected from a group of five 
infected mosquitoes from day 8 to day 26 post-infectious 
blood meal.
Western‑blot assay
The extracts of 1 ×  104 salivary gland Spz of PfCSP/Py, 
P. falciparum 3D7, or wild-type P. yoelii 17XNL were 
placed in sample buffer containing 2  % sodium dode-
cyl sulfate (SDS), 10 % glycerol, and 0.005 % bromophe-
nol blue for 10 min. The extracts were then subjected to 
SDS–PAGE and electro-blotted onto PVDF membranes. 
The membranes were blocked by 5 % no-fat milk in TBST 
and incubated for 1 h with mAb, 2A10 specific for PfCSP 
repeats, or 2F6 specific for PyCSP repeats. After it was 
washed three times with Tris-buffer containing 0.05  % 
Tween-20, the membrane was incubated with goat anti-
mouse IgG (H+L) antibody, which was detected using 
Pierce ECL western blotting substrate (Thermo Fisher 
Scientific Inc., Waltham, MA, USA).
Immunofluorescence assay
Five× 103 salivary gland Spz of PfCSP/Py or wild-type 
P. yoelii 17XNL were loaded onto MP Biomedical multi-
test slides. After they were air dried at room temperature 
for 2 h, the slides were fixed with 4 % paraformaldehyde 
for 10 min, and then blocked with 3 % BSA in PBST. The 
slides were incubated with 2A10 for 45  min. After they 
were washed three times with PBS containing 0.05  % 
Tween-20, the slides were incubated with Alexa Fluor 
594 goat anti-mouse IgG (H+L) antibody (Thermo 
Fisher Scientific Inc, Catalogue#: A-11005). After 1 h, the 
slides were washed and mounted in PBS containing 50 % 
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glycerol and 1  % (w/v) p-phenylenediamine to reduce 
bleaching.
Sporozoite infectivity
Infectivity of PfCSP/Py SPZ was determined in female 
BALB/c mice by two different methods. In the first 
method, mice were injected intravenously (iv) with 50, 
150 and 450 Spz of PfCSP/Py or wild-type P. yoelii dis-
sected from salivary glands. In the second method, mice 
were exposed to the bite(s) of one, five or ten PfCSP/
Py parasite-infected mosquitoes. In both methods, the 
parasitaemia of the challenged mice was determined by 
microscopic examination of Giemsa-stained thin blood 
smears, obtained from days 3 to 10 post-Spz challenge.
ELISA assay
Levels of antibody in mice immunized with PfCSP/Py 
immunized mice were determined by ELISA. Mouse 
Fig. 1 Generation of transgenic PfCSP/Py parasites. a Transgenic parasites were generated by inserting the PfCSP expression construct at the locus 
of the P. yoelii CSP gene by double cross-over homologous recombination. b Correct targeting was checked by gDNA PCR. Primers used in these 
experiments were listed in Table 1
Table 1 List of primers used for plasmid construction
Amplified region Forward primer Reverse primer
PyCSP promoter CTATCAAATAATGTACTGCCCTTAAAAGC GCTAATTTTCTCATCATTTTAAATATGTGTGTGTATATATAAG
PfCSP ORF CATATTTAAAATGATGAGAAAATTAGCTATTTTATCTG aaagtcgacGTTGTTCTTAATGATTCAATGCACGGTG
Three regions of PyCSP gene aaaggatccGTATTGTGAACTTTCCTCATTTATTACG aaagcggccgcCATATTTATGTACACCCTTTTGTGGACC
PyCSP primer forward CTACGTAACAAATATGCAAGATGG
PyCSP primer reverse CATATCCTGGAAGTAGAGAATCAAC
PyCSP primer reverse AGAACCCTTGTGTTTGACGAAC
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sera collected before vaccination were used as a negative 
control. The ELISA plates were first coated with a recom-
binant full-length PfCSP (10  μg/ml) and then blocked 
with 3 % BSA in PBS-T. Mouse sera were twofold diluted 
(1:200–1:12,800) and added to the plates and incubated 
for 1  h. After washing the plates, HRP-conjugated goat 
anti-human IgG Fc Fragment was added. After TMB 
High Sensitivity Substrate was added, ODs were read 
at 450 nm. Mouse sera collected 1 day before challenge 
were analyzed for antibody titres against PfCSP.
Mouse protection assay
Female BALB/c mice were immunized once or twice by 
iv injection with different doses of gamma-irradiated 
PfCSP/Py Spz, as described in Table  4. The interval 
between the priming and boosting was 14  days. Four-
teen days after priming or boosting dose, mice were 
challenged by iv injection with 50 live PfCSP/Py Spz. Par-
asitaemia was determined by microscopic examination 
of Giemsa-stained thin blood smears, obtained at 7 days 
post-Spz challenge.
Results
Biological properties of PfCSP/Py parasites
A hybrid P. yoelii parasite has been generated by replac-
ing full PyCSP with full PfCSP via double cross-over 
recombination. The full-length CSP is under the regula-
tion of PyCSP untranslated regions (UTRs) (Fig. 1). The 
PfCSP/Py parasite completed the life cycle in Anopheles 
mosquitoes, and produced midgut and salivary gland Spz 
higher than or comparable to wild-type P. yoelii parasites 
(Fig. 2). For both PfCSP/Py and wild-type parasites, the 
date of highest number of midgut and salivary gland Spz 
post-infectious blood meal was around day 10 and day 
14, respectively. The range of days with >10,000 salivary 
gland Spz per mosquito is 9  days long (day 10–day 18) 
for PfPy parasites, which is 5 days longer (day 12–day 16) 
than the wild-type counterpart.
The hybrid PfCSP/Py Spz were recognized by 2A10 
mAb, an antibody that specifically reacts with the cen-
tral repeats of the PfCSP [27]. The 2F6 mAb, an antibody 
that reacts with the central repeats of the PyCSP [28, 29], 
had no reactivity to the hybrid PfCSP/Py Spz (Fig. 3). The 
immunoblot and immunofluorescent assay showed that 
the PfCSP/Py Spz expressed PfCSP, but not PyCSP.
Titration of the PfCSP/Py Spz infectivity
BALB/c mice were injected intravenously with 50, 150 
or 450 PfCSP/Py Spz or wild-type P. yoelii Spz, and 
monitored development of blood stage infection in the 
mice on days 3–5 post challenge. The PfCSP/Py Spz 
were highly infective, similar to wild-type P. yoelii Spz 
(Table 2). The appearance of erythrocytic stage parasites 
was observed 4  days post challenge in all of the mice 
injected with the low dose of PfCSP/Py Spz, whereas four 
out of five mice challenged with 50 wild-type P. yoeli Spz 
became positive.
Then the infectivity of PfCSP/Py Spz was evaluated in 
mice delivered by mosquito bite (Table 3). BALB/c mice 
were exposed to the bites of one, five or ten PfCSP/Py-
infected mosquitoes. It was found that the bite of one 
PfCSP/Py-infected mosquito induced blood infection in 
17 % (1/6) of mice, whereas five or ten bites of five or ten 
PfCSP/Py-infected mosquitoes induced blood infection 
in all (6/6) mice.
Protective efficacy of radiation‑attenuated PfCSP/Py Spz
Then the protection of BALB/c mice following immuni-
zation with gamma-irradiated PfCSP/Py Spz was inves-
tigated. The mice immunized with one dose of 50,000, 
100,000 or 200,000 irradiated PfCSP/Py Spz were all 
infected by day 7 post challenge with PfCSP/Py Spz. The 
mice immunized with two doses of 25,000, 50,000, or 
100,000 PfCSP/Py Spz were protected in a dose-depend-
ent manner against PfCSP/Py Spz challenge. The majority 
of mice (3/4) were protected in the group that received 
highest prime boost vaccination dose of 100,000/100,000 
(Table 4).
The titres of antibody against PfCSP induced in the 
sera of mice immunized with irradiated PfCSP/Py Spz 
were determined  (Fig.  4). The sera were collected 1  day 
before challenge, or 13  days post boost. The CSP anti-
body titres of protected mice were higher than 2000, 
whereas the titres in mice that were not protected were 
lower than 2000 (Fig. 4). It is noteworthy that some mice 
Fig. 2 Hybrid PfCSP/Py parasites produced sporozoites in mosquito. 
Three-hundred female Anopheles mosquitoes fed on five Swiss-
Webster mice infected with wild-type P. yoelii or transgenic PfCSP/Py 
parasites with 0.1 % gametocytaemia. Mosquito midguts and salivary 
glands from five mosquitoes were dissected from day 8 to day 26 
post mosquito-infectious blood meal
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that mounted high anti-CSP antibody titres were not 
protected, thus indicating that other immune responses 
may account for the overall protection.
Discussion
The complete P. falciparum life cycle cannot be main-
tained in  vitro in the laboratory, thus limiting the 
experimental study of the Spz of P. falciparum human 
malaria parasite. Laboratory mouse malaria models 
have provided alternative platforms for human malaria 
research. Rodent malaria (P. yoelii, P. berghei, Plasmo-
dium chabaudi, and Plasmodium vinckei) isolated from 
wild thicket rats have been adapted to grow in labora-
tory rodents. These species display many of the biological 
characteristics of the human malaria parasite and rodent 
models of malaria have been widely and successfully used 
to complement research on P. falciparum [30, 31].
Although recombinant rodent P. berghei parasites 
expressing PfCSP repeats or a full-length PfCSP were 
generated, their infectivity in mosquito salivary glands 
was lower than that of wild-type parasites. Here, P. yoelii 
Fig. 3 PfCSP/Py sporozoites (Spz) express Plasmodium falciparum CSP. a Immunoblots of PfCSP/Py, P. falciparum (Pf ), and P. yoelii (Py) SPZ, using 
mAb 2A10 (recognizes PfCSP) and mAb 2F6 (recognizes PyCSP). The bottom bands represent processed products. b Staining of live Spz with mAb 
2A10 that recognizes the central repeats of PfCSP
Table 2 Titration of  the infectivity of  PfCSP/Py Spz 
through intravenous injection
a Number of infected mice/number of challenged mice. Infection was defined 




Day 3 post 
challengea
Day 4 post 
challenge




450 0/5 5/5 5/5
150 0/5 5/5 5/5
50 0/5 4/5 5/5
PfCSP/Py 450 0/5 5/5 5/5
150 0/5 5/5 5/5
50 0/5 5/5 5/5
Table 3 Titration of  the infectivity of  PfCSP/Py Spz 
through the bite(s) of infected mosquitoes
a 80 % of An. stephensi mosquito was infected with PfCSP/Py Spz in the salivary 
gland. Individual salivary glands were examined after each feed to ensure that 
mice received the indicated number of infected bites
b Infection was defined as the observation of blood stage parasites in thin 
blood smears by Giemsa staining
c Pre-patent period (PPP), number of days after Spz inoculation until detection 
of blood stage parasites in Giemsa-stained thin blood smears
No. bitesa Infectedb/total 
mice
% patent PPP (days)c
BALB/c mice 1 1/6 17 % 5
5 6/6 100 % 4.2
10 6/6 100 % 3.8
Table 4 Protection of immunized BALB/c mice
a The interval between the priming and boosting with irradiated PfCSP/Py Spz 
is 14 days
b Mice were challenged by iv injection of 50 live, non-irradiated salivary gland 
PfCSP/Py Spzs. The infection was evaluated by the presence of parasites in thin 
blood smears upon Giemsa staining on 7–14 days post Spz challenge
Vaccination/boost dosea No. infected mice/
no. challenged miceb
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17XNL was used [32], which produces high number of 
Spz in mosquito salivary glands and is infectious to mice 
of both BALB/c and C57BL/6 strains [33], as the parental 
line for generating the PfCSP/Py transgenic parasites. The 
CSP, the major antigen on the Spz surface, is composed of 
the N-terminal flanking region, the repetitive immuno-
dominant B-cell epitope containing central region, T-cell 
epitope containing C-terminal flanking region. The N- 
terminal regions play essential roles in parasite infectiv-
ity and could be targeted by protective antibodies [34]. In 
this study, a transgenic P. yoelii parasite clone that is able 
to express a full-length PfCSP was successfully generated 
and its biological properties compared to those of wild-
type P. yoelii parasite were investigated.
A novel clone of a transgenic P. yoelii parasite that is 
able to express a full-length PfCSP, named PfCSP/Py 
parasite, was generated. This PfCSP/Py parasite clone 
can produce up to 30,000 Spz in mosquito salivary gland, 
which are equal or even higher than the number of Spz 
produced by wild-type P. yoelii (Fig.  2). The number of 
days for collecting high numbers of salivary gland PfCSP/
Py Spz (>10,000/mosquito) is around 9 days, which pro-
vides a wider range of working days for researchers than 
wild-type P. yoelii. When mice were exposed to the bites 
of PfCSP/Py-infected mosquitoes, it was found that bites 
of five PfCSP/Py-infected mosquitoes could induce blood 
infection in all of the mice (Table 3). This indicates that 
PfCSP/Py-infected An. stephensi mosquitoes can trans-
mit malaria as efficiently as P. yoelii-infected An. ste-
phensi mosquitoes, as demonstrated in a previous study 
[35]. The current study only compared the Spz numbers 
of PfCSP/Py parasites with those of wild-type P. yoelii 
through transmission from Swiss-Webster infected mice 
to An. stephensi mosquitoes. It is noteworthy that the 
parasites’ infectivity by transmission from other mouse 
strains, such as BALB/c and C57BL/6, to other mosquito 
species, such as Anopheles freeborni and Anopheles gam-
biae, requires further investigation.
The P. falciparum CSP has been regarded as one of the 
best vaccine candidates for malaria. Transgenic rodent 
malaria Spz expressing P. falciparum CSP represent 
a unique tool to evaluate PfCSP-based immunity and 
systematically assess formulation, molecular composi-
tion and regimen of a human malaria vaccine using a 
high-throughput animal experimental model. Although 
a recombinant rodent P. berghei parasite expressing 
PfCSP repeats was generated a decade ago, its infectiv-
ity in mosquito salivary glands has been modest, i.e., 
approximately 3000 per mosquito [8]. The infectivity 
of a more recently established, recombinant P. berghei 
parasite expressing a full-length PfCSP, is even less, i.e., 
only 1800 Spz are produced in the salivary gland [21]. 
The sequence changes introduced outside the conserved 
regions I and II by replacing PbCSP with PfCSP could 
possibly have reduced the ability of the PfCSP protein 
to function optimally within the P. berghei background 
during Spz invasion of An. stephensi salivary glands [21]. 
Thus, the yield of a low number of salivary gland Spz has 
probably hampered further PfCSP-based immunity and 
vaccines research, such as vaccination using irradiated 
PfCSP/Py Spz, which would require at least a million Spz 
per study.
Protective immunity induced by irradiated PfCSP/
Py Spz has also been investigated. The protection rate 
of the mice that were immunized with the higher dose 
of vaccine (100,000/100,000) was much higher than 
that of mice that received the lower dose of vaccine 
(25,000/25,000). ELISA assay showed that there was a 
correlation between the titres of anti-PfCSP antibody and 
protection of the PfCSP/Py-vaccinated mice.
Lastly, when the titres of anti-PfCSP antibody titres 
were determined, there was a trend that mice that 
received a higher number of PfCSP/Py Spz produced 
a higher titre of anti-PfCSP. However, it is notewor-
thy that some mice that can mount higher anti-CSP 
antibody titres were not protected. This indicates that 
other immune responses may account for the overall 
protection.
Kumar et al. reported that the CSP is an immunodomi-
nant protective antigen in irradiated Spz [9], but Grüner 
et  al. reported that sterile protection against malaria is 
independent of immune responses to the CSP [36]. In 
this regard, the authors are currently planning to conduct 
a comprehensive and independent study using heter-
ologous immunization and challenge combinations with 
Fig. 4 Antibody titres against PfCSP in the sera of PfCSP/Py-
immunized mice. BALB/c mice were twice immunized with PfCSP/
Py Spz. One day before challenge with live PfCSP/Py Spz, the sera 
were collected and the antibody titres were determined by ELISA. Red 
and black symbols represent the protected and non-protected mice 
(shown in Table 4), respectively
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PfCSP/Py parasites and wild-type P. yoelii parasites in 
order to address this controversial issue.
Conclusions
In summary, the current study has demonstrated a suc-
cessful establishment of a transgenic P. yoelii parasite 
clone that is able to express the full-length PfCSP, PfCSP/
Py parasite. Importantly, this PfCSP/Py parasite can be as 
infectious as, or even more than, wild-type P. yoelii para-
site both in mosquito vector and in mouse, a mamma-
lian host. This indicates that the expression of the PfCSP 
transgene does not interfere with the infectivity and fit-
ness of the parasite. The new transgenic parasite that 
expresses a full-length PfCSP may become a useful tool 
for researchers to investigate immunity against PfCSP in 
a mouse model.
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